Mölnlycke at a glance

The grand opening brought together business partners and thought leaders from industry, academia and healthcare. A highlight was a panel discussion entitled “Who should lead the transformation towards sustainable healthcare,” featuring: Petra Noreback, State Secretary to the Minister for Social Affairs and Public Health Christian Cederholm, Chief Executive Officer of Investor AB Boubou Hallberg, Chief Executive Officer of Sahlgrenska University Hospital Jenny Nyström, Dean of Sahlgrenska Academy at the University of Gothenburg Emma Wright, Chief Medical Officer, Mölnlycke Zlatko Rihter, Chief Executive Officer, Mölnlycke  The discussion underscored the urgency—and opportunity—of transformation towards sustainable healthcare, as well as the critical role of cross-sector collaboration to achieve this. Zlatko Rihter, CEO, Mölnlycke commented “We’re proud to open the doors of our new HQ for this special evening. Our move to GoCo Health Innovation City was driven by our ambition to foster partnerships to speed up innovation towards sustainable healthcare; and this was echoed by the panel who spoke about the importance of collaboration to drive true change that benefits both people and planet.”   The new headquarters triples Mölnlycke’s laboratory space, significantly expanding its capacity for research and development. Designed for flexibility, collaboration and employee wellbeing, the headquarters sets a new standard for sustainable and future-ready workplaces. Positioned within one of Sweden’s most dynamic life science ecosystems, the facility enhances Mölnlycke’s ability to attract top global talent and co-create with health innovators. “This wonderful building is more than just bricks and mortar—it embodies the boldness and passion that define Mölnlycke,” Rihter added. “We’re excited to be part of a community that shares our vision of smarter, safer and more sustainable healthcare.” With this investment, Mölnlycke reaffirms its commitment to Sweden’s MedTech leadership—and to revolutionising care for people and planet. For more information, please contact:  [Contact card] Sofia Lindqvist

Mölnlycke has committed to reaching net zero greenhouse gas emissions across the value chain by 2050. Specifically, the company has committed to reducing absolute Scope 1 and 2 GHG emissions by 90% by 2050 compared to the 2021 base year, and to reducing Scope 3 GHG emissions by 97% per tonne of sold product within the same timeframe.* “This validation represents a critical step in executing our strategy to drive decarbonisation of healthcare. Reaching net zero demands measurable action, close collaboration, and innovation across the entire value chain. Mölnlycke is fully committed to working with its partners, suppliers, and customers to drive progress and deliver concrete outcomes”, says Caterina Camerani, VP Sustainability at Mölnlycke. The company to reach its near-term GHG emission reduction targets and achieved significant progress in 2024 with 100% of renewable electricity at all manufacturing sites and the headquarters, as well as a reduction of 40% in Scope 1 and 2 and 19% in Scope 3 GHG emissions** versus 2021 base year. *The target boundary includes land-related emissions and removals from bioenergy feedstocks. **Scope 3 GHG emissions from the relevant categories (1,3,4,5), as validated by SBTi for near-term targets. For more information, please contact:  [Contact card] Sofia Lindqvist    

This collaboration involves clinicians, materials management and procurement teams, regulators, and industry experts, aiming to enhance patient care through clinically relevant and consistent evaluations. Mölnlycke Health Care has been a steadfast supporter of the WCCC from the start, working alongside other major wound care players on the project to improve patient outcomes. In a recent publication in the Wounds journal, the WCCC calls for a new era of wound dressing standards rooted in clinical relevance, biological validity, and consistency across product development and evaluation. Standardised, meaningful testing is not just about better comparisons—it is about fostering innovation. A clear, testing framework that is shared by all stakeholders: Helps clinicians make better-informed decisions based on consistent, evidence-based product evaluations, recognised by various stakeholders Progresses industry design and drives refinement of products with real-world performance in mind Helps researchers and regulators agree on functional dressing properties that align with clinical needs and ensure that pre-clinical testing appropriately reflects these needs  Dr. Sarah Griffiths Langbord, chair of the WCCC Gaps Dressing Standards Work Group, explains that the initiative has developed from an imminent need for standardisation. “Wound dressings are currently evaluated using various test methods, many of which are incompletely specified or insufficiently relevant to real-world wound care scenarios. This has resulted in individualised modifications by test users with no established best practices and no consistent baseline set of standardised tests for pre-clinical evaluations.” PhD Erik Nygren is Senior Scientist at Mölnlycke Health Care and one of several industry representatives on the work group. Nygren emphasises the importance of a unified framework to enhance the overall quality and clinical performance of wound dressing products. “During development, reliable, clinically relevant test methods are a prerequisite to achieve wound dressings with the right properties, which will meet true needs of clinicians and patients. By sharing knowledge and capabilities within the WCCC Gaps Work Group, we can accelerate progress and foster a unified community that benefits all stakeholders.” The WCCC urges the wound care community to get involved, as they need feedback from a wide range of stakeholders including clinicians, materials management and procurement teams, regulators, and industry experts. By identifying gaps in current standards, the WCCC can drive innovation in wound dressing development, shape research priorities, and highlight external funding opportunities to support pre-clinical research. Stakeholders can help the WCCC by taking a survey here: https://bit.ly/4cN7sIZ Read more about the WCCCs initiative to improve wound care standards here: https://www.hmpgloballearningnetwork.com/site/wounds/enhancing-patient-care-through-advanced-wound-dressing-standards-wound-care For more information, please contact:  [Contact card] Sofia Lindqvist

“Our strong financial position and continued growth allow us to direct our future and continued investments. At the same time, it is clear that our strategy and previous investments have paid off, enabling close relationships with our customers working alongside them to handle the challenges of healthcare today,” says Zlatko Rihter, CEO of Mölnlycke. Highlights from the year: Continued strong growth at 7.4% compared to previous year and annual sales of EUR 2,064 million with improved profitability. The progress in becoming a leader in sustainable healthcare was recognised with a platinum medal from EcoVadis. Focus on transformation through partnerships commenced in 2024 with the acquisition of P.G.F. Industry Solutions, the strategic partnership with Ondine Biomedical Inc and strategic investments in MediWound and Siren. The joint venture Tamer Mölnlycke Care in Saudi Arabia has started production and there are plans for expansion in India and China. Download and read the full report on www.molnlycke.com/corporate/about/reports For more information, please contact:  [Contact card] Sofia Lindqvist

Barcelona, Spain. 27 March 2025. New study reports that switching patients with chronic wounds to the multi-layered, bordered silicone-coated foam dressing, Mepilex® Border Flex, alongside a clinician educational support programme, resulted in a significant reduction in the number of dressing changes being undertaken and a reduction in dressing-related costs.1  The study, sponsored by Mölnlycke Health Care, and conducted across primary care facilities in Seville, Spain was today presented as an e-poster at the 35th Conference of the European Wound Management Association (EWMA) 2025 in Barcelona, Spain by the principal investigator Dr Andres Roldan Valenzuela, Centro de Salud Mairena del Aljarafe – Cuidad Expo, Seville. The primary outcome of the study was a statistically significant reduction in the number of dressing changes undertaken, prior to and after the switch from a bordered foam dressing (baseline) to  Mepilex® Border Flex; results demonstrated the median number of dressing changes reduced during the study period, from three in a seven-day period to just one.1 Other reported outcomes included:1 32% wounds healed by the final visit 50% reduction in wound area in four weeks in 75% of patients Two thirds (68.7%) reduction in wound area from baseline to the final visit Reduced pain at dressing changes (pain severity scores of 3.1 - 3.3 at baseline associated with previously used dressings, compared to scores of 0.5 - 1.1 recorded with Mepilex® Border Flex at the final visit) 44% reduction in weekly dressing cost per patient (5.38€ less after the dressing switch) No dressing related adverse events Almost all (97%) of the clinicians rated the overall performance of Mepilex® Border Flex to be better than the previously used dressings, while 100% of patients rated Mepilex® Border Flex as ‘good’ to ‘very good’ in terms of overall satisfaction, compared to 65% for the previously used dressings. Dr Andres Roldan Valenzuela, principal investigator commented “The results of this study clearly demonstrate how simple changes to a wound care treatment regime can bring about positive outcomes for both patients and healthcare providers. At a time when healthcare systems and staff are under increasing pressure on both cost and time it is encouraging that there are solutions to help drive efficiencies and improve outcomes for all involved.” For more information, please contact:  [Contact card] Sofia Lindqvist About the study design The study involved 37 adult patients, aged between 30 and 90+ years presenting with wounds that had not reduced in size by >40-50% in the previous month and had been managed with foam dressing (other than Mepilex® Border Flex), for a minimum of four weeks (baseline). Category 2 pressure ulcers (24.3%) and venous leg ulcers (18.9%) were the most common wound types. Patients in the study had Mepilex® Border Flex applied to their wounds for ≥4 weeks, in conjunction with standard of care.  

The Tamer Mölnlycke Care joint venture was initiated in 2021 with the agreement to develop a customised surgical procedure tray factory in Saudi Arabia, with first production expected in Q4 2024. The increased investment allows for an expansion in the range of Mölnlycke products manufactured and distributed in the country and to the neighbouring region. Adding drapes and gowns, emollient range and selected wound care products to the offering allows more healthcare professionals and patients in the region to benefit from Mölnlycke products and solutions. Zlatko Rihter, CEO, Mölnlycke Health Care comments “To ensure we meet customer demand, geographical expansion is a strategic priority for Mölnlycke Health Care. Increased investment in our existing long-term partnership with Tamer Group will importantly enable healthcare professionals and patients in Saudi Arabia access to our quality products and solutions helping to improve outcomes, and is a step closer to realising the potential of this rapidly growing healthcare market.” Speaking on behalf of Tamer Group, Chairman Ayman Tamer adds “This investment is key to enabling future growth in the region as outlined in the Saudi Vision 2030 - supporting the regional healthcare ecosystem, including exporting goods to the Middle East and Africa region, whilst developing local skills and expertise.” Mahmoud Wagih, CEO, Tamer Mölnlycke Care comments “I am delighted to lead this business where Mölnlycke and Tamer will build a strong, long-term successful joint venture, bringing superior health care solutions to our region.” The Tamer Mölnlycke Care joint venture is a long-term agreement between two organisations who have been working in partnership over the past decade; and are committed to meeting customer demand in the evolving healthcare landscape of Saudi Arabia and the wider region. For more information, please contact:  Liz Neal Director of Communications Email: liz.neal@molnlycke.com Phone: +44 7787432560  

Gothenburg 12 April 2024: Mölnlycke, a world leading MedTech company specialised in wound care and wound management, announced today it signed an agreement to acquire P.G.F. Industry Solutions GmbH, the Austrian manufacturer of Granudacyn wound cleansing and moisturising solutions. Mölnlycke and P.G.F. have worked together for five years on the manufacturing and distribution of Granudacyn, a range of solution and gel products intended for use in the cleansing, irrigation and moisturisation of various wound types. The high quality and composition of Granudacyn ensures good biocompatibility, allowing it to be effectively used on a broad range of tissues in burns, as well as acute and chronic wounds. Mölnlycke currently distributes Granudacyn in over 50 countries around the world. “With an ageing population in combination with increased chronic wounds, such as diabetic foot ulcers or venous leg ulcers, it is our obligation to help ease the burden of wounds on national healthcare regimes” says Zlatko Rihter, CEO of Mölnlycke Health Care. “The acquisition of P.G.F. and its state-of-the-art manufacturing plant, will allow Mölnlycke to aggressively expand our Granudacyn business to improve the lives of even more patients.” “I’m excited for P.G.F. to become part of Mölnlycke and for the team to continue to manufacture products that support Mölnlycke’s Wound Care mission to help free patients from the burden of wounds” says Peter Fritz, P.G.F. founder and CEO, who will continue to lead this team and manufacturing process from P.G.F.’s Austria headquarters. Closure is expected after certain milestones are reached and will be communicated separately. For more information, please contact: Jennifer Doak Global Communications Director Wound Care Email: jennifer.doak@molnlycke.com Phone: +1 678 206 6179 About Mölnlycke® Mölnlycke Health Care is a world-leading MedTech company that specialises in innovative solutions for wound care and surgical procedures. Mölnlycke products and solutions are used daily by hospitals, health care providers and patients in over 100 countries around the world. Founded in 1849, Mölnlycke is owned by Investor AB and headquartered in Sweden. www.molnlycke.com About P.G.F. Industry Solutions P.G.F. Industry Solutions was founded in 2005 by Peter Fritz to develop and produce ecologically compatible hypochlorous acid based products to protect the user and their environment. The company is founded on more than 30 years of experience in research, development, production, and worldwide distribution of medical and measurement products. P.G.F. employs approximately 25 employees and is headquartered in Elixhausen, Austria. www.veriforte.com.

The facility is backed by a group of seven leading global and regional banks, well diversified to match Mölnlycke’s geographical footprint. The banks are BNP, Danske Bank, HSBC, ING, JP Morgan, Nordea and SEB as mandated lead arrangers. SEB acted as the coordinator, documentation agent and facility agent for the transaction. For more information, please contact:  Liz Neal Director of Communications Email: liz.neal@molnlycke.com Phone: +44 7787432560 About Mölnlycke   Mölnlycke is a world-leading medical products and solutions company that equips healthcare professionals to achieve the best patient, clinical and economic outcomes. The core business is within the four Business Areas Wound Care, Operating Room Solutions (ORS), Gloves and Antiseptics.  Mölnlycke employs around 8,700 people. The headquarters are in Gothenburg, Sweden, and the company operates in more than 100 countries worldwide. Mölnlycke is owned by Patricia Industries AB, which is part of Investor AB, an engaged owner of high-quality, global companies founded by the Wallenberg family in 1916. www.molnlycke.com 

“At Mölnlycke, we believe that education is a cornerstone of progress in healthcare. The 2025 Future Summit exemplifies our commitment to fostering innovation, enhancing clinical practice, and building partnerships that enable healthcare professionals to improve patient outcomes”, says Emma Wright, Chief Medical Officer at Mölnlycke Health Care. “We are thrilled to bring together such a diverse and accomplished group of experts to shape the future of wound care.” Offering a unique platform for collaboration Set to be a highlight of the professional education calendar, the 2025 Future Summit will host over 130 HCPs from vascular, orthopedic, general, and plastic surgery specialties. With the participation of global faculty leaders, the event will provide a unique platform to explore cutting-edge advancements, share best practices, and foster interdisciplinary collaboration in wound care and surgical excellence. The summit will take place on October 6-7, 2025, in the Netherlands and will be presided over by renowned experts Professor Javad Parvizi and Mr. Ibby Younis.  “The Future Summit reflects the power of partnership and education in driving medical advancements,” says Professor Javad Parvizi, co-president of the summit. “By bringing together experts from diverse specialties, this event creates a unique opportunity to exchange knowledge and redefine standards in wound care and surgery.” A catalyst for innovation Attendees of the summit will be provided with the opportunity to engage in meaningful dialogue, access the latest clinical insights, and participate in interactive workshops led by global faculty leaders.  “This summit is not just an event; it is a catalyst for innovation. It empowers clinicians from across EMEA to collaborate, learn, and apply transformative approaches that will ultimately improve patient care. Mölnlycke’s unwavering commitment to education is truly commendable,” says Mr. Ibby Younis, co-president of the summit.   For more information, please contact:  Sofia Lindqvist  Media Relations Manager Email: sofia.lindqvist@molnlycke.com   Phone: +46 72 255 35 09